ginette-35

Ginette-35 (Ethinyl, Estradiol, Cyproterone)

Strength(s): 2 mg

Active Ingredient: Ethinyl, Estradiol, Cyproterone

Category:

Product Description

Ginette-35 medication is a pill that is used to treat females with severe signs of androgenization which is an overproduction of androgen. It results in conditions like hirsutism (unwanted hair) and androgenic alopecia (hair loss). These conditions lead to acne, inflammation, and seborrhoea which is greasy skin from too much sebum. Ginette-35 medication reduces the symptoms of androgen-dependent conditions where antibiotics or local medicine hasn’t been successful.

Individuals with such conditions should Order Ginette-35 online Ginette-35 medication pills can also be an oral contraception and polycystic ovary syndrome. Excess androgen production also causes polycystic ovary syndrome and mostly accompanied by acne and hirsutism. This medication inhibits the hyperandrogenic state very efficiently, and when you use it for long, it offers great relief from these ailments and at the same time suppressing pregnancy by blocking ovulation. It prevents all cervical secretions from reaching the sperm getting through and hindering the development of the endometrium. Therefore, the ovum cannot attach to the placenta.

The cyproterone component can also be a substitute for Spironolactone as the anti-androgen agent of transgender feminizing hormone therapy for male to female transgenders if small doses of anti-androgen are required.

Ginette-35 medication active ingredients

Ginette-35 medication pill contains Ethynyl Estradiol and Cyproterone Acetate. Cyproterone Acetate is a unique agent that has a particular kind of progestin which has anti-androgenic and anti-male hormone influences. On the other hand, Ethynyl Estradiol is the most common form of estrogen in combined hormonal and contraceptive pills.

Mode of action

Cyproterone in Ginette-35 tablets blocks the production of androgens by the ovaries and binds to the androgen receptors in specific cells in the skin, containing sebum glands and hair follicles thus blocking the action of androgens in overproduction of sebum and overproduction of hair. Ethynyl Estradiol enhances the effect of Cyproterone agent by reducing the amounts of androgen in blood circulation, therefore, relieving symptoms like acne and hirsutism

The most common side effects of Ginette-35 medication are:

  • Breast tenderness
  • Abdominal pain
  • Nausea
  • Oedema
  • Headache
  • Skin rash and itching
  • Insomnia
  • Depression

Less common side effects of Ginette-35 medication are:

  • Fluid retention
  • Changes in body weight
  • Changes in libido

Do not buy Ginette-35 medication from a pharmacy or online if:

  • You are taking another form of oral contraceptives
  • You are allergic to any ingredient in the medicine like ethynyl oestradiol or cyproterone
  • You have hypertension or lipid disorders
  • You have deep venous thrombosis, heart attack or stroke
  • Persons with abnormal genital bleeding
  • You are pregnant or planning to conceive
  • You are taking other pills that may interact with Ginette-35 medication such as Nevirapine, Rifabutin or Antibiotics such as Penicillin
  • You have diabetes with changes to blood vessels or diabetic and taking antidiabetics or insulin and especially without consulting your doctor
  • You have some genetic preexposure or history of carcinoma of the breast, endometrial or liver disease

Persons who Order Ginette-35 online should note that combination contraceptives like Ginette-35 increase the risk of breast cancer, thrombosis which can have grave consequences depending on where the clot forms and additional use of hormonal contraceptives since it will expose you to an excessive dose of hormones

How to use

Each pack of Ginette-35 contains 21 tablets. A patient should take one pill a day for 21 days followed by seven days off, during which you should have menstrual bleeding.

Reviews

There are no reviews yet.

Be the first to review “Ginette-35 (Ethinyl, Estradiol, Cyproterone)”

Your email address will not be published. Required fields are marked *